CD274 and non-small cell lung carcinoma: The current findings regarding the clinical value of local therapy within the PD1/PD-L1 inhibitor window in patients with AR were comparable to those reported in patients with metastatic NSCLC treated with the PD1/PD-L1 inhibitor who developed acquired resistance [22,23,38].